Akston Biosciences ^{Filed Terms, NYSE American: AXTN}

We are a pet biotechnology company focused on the development and commercialization of innovative biopharmaceutical products for cats, dogs, and other companion animals. We believe the pet health market is experiencing rapid growth, with increasing demand for innovative treatments that enhance pet longevity and quality of life. Monoclonal antibodies, or mAbs, have emerged as a therapeutic class in companion animal health, already driving over a billion dollars in annual sales globally. However, current mAb therapies come with limitations, including high costs and frequent dosing requirements. Our Ambifect® platform is designed to help overcome these challenges, offering a potentially transformative approach that reduces the number of doses required of traditional mAb therapies while significantly lowering costs. We believe this positions us to capture and expand market share, potentially setting a new standard for innovation in veterinary medicine. Our proprietary Ambifect® Fc-fusion protein platform is engineered to induce and sustain the production of therapeutic antibodies for cancer, dermatitis, and pain. It works by presenting validated disease-target molecules to the immune system, promoting the development of target-specific immune cells and the subsequent generation of disease-specific therapeutic antibodies as illustrated in the figure below.